In terms of latest development, QIAGEN’s market-leading QuantiFERON latent TB test delivered an outstanding second quarter of 2023, ...

All ELI students from a country that has been identified as high-risk must be tested for Tuberculosis using the Quantiferon test before coming to Delaware. After taking the Quantiferon test, the ...

The QuantiFERON test delivered its sixth consecutive quarter of sales above $100 million, supported by solid demand in all regions from conversion gains against the tuberculin skin test.

Qiagen sees Q1 sales up ~5% to $483M, topping prior outlook despite missing street consensus. QIAstat-Dx and QuantiFERON test drive growth; EPS raised to $2.35 amid early margin target achievement.

The hazard ratio for the primary endpoint of sustained QFT test conversion was 1.04 (95% CI 0.73-1.48) with revaccination versus placebo, for a vaccine efficacy point estimate of -3.8% (95% CI ...